Related Experiment Videos
Methysergide (Sansert) treatment in acute stroke. Community pilot study
Angiology
|March 1, 1985
Summary
Serotonin (5-HT) may contribute to stroke damage. Blocking serotonin effects with agents like Sansert could reduce stroke-related disability and mortality.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular Medicine
Background:
- Serotonin (5-HT), discovered in 1948, exhibits potent vasoactivity.
- Elevated CSF serotonin levels are documented in cerebrovascular disease.
- Altered serotonin metabolism is hypothesized to underlie stroke pathophysiology.
Purpose of the Study:
- To investigate the role of serotonin in stroke.
- To explore the potential of serotonin-antagonizing agents in mitigating stroke damage.
Main Methods:
- Laboratory testing of biogenic amine inhibitors.
- Evaluation of serotonin's role in experimental and human stroke models.
Main Results:
- Promising data suggests reduced damage and disability with serotonin inhibition.
- Experimental evidence supports the hypothesis of serotonin's involvement in stroke.
Conclusions:
- Pharmacological blockade of serotonin effects presents a therapeutic opportunity.
- Sansert (methysergide) warrants clinical trials for stroke management.